We noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
Printable Handouts
Navigable Slide Index
- Introduction
- Replicative cycle of HIV
- HIV reverse transcriptase (1)
- Nucleoside reverse transcriptase inhibitors
- HIV reverse transcriptase (2)
- Zidovudine
- Original paper describing zidovudine
- Didanosine
- Zalcitabine
- Stavudine
- Original paper describing stavudine (1)
- Original paper describing stavudine (2)
- Lamivudine
- Abacavir
- Emtricitabine
- Mechanism of action of AZT
- Nucleotide reverse transcriptase inhibitors
- Tenofovir
- Original paper describing Tenofovir
- Mechanism of action of Tenofovir
- Non-nucleoside reverse transcriptase inhibitors
- HIV reverse transcriptase (3)
- The first NNRTI
- Tivirapine/Emivirine
- Nevirapine
- Delavirdine
- Efavirenz
- Etravirine
- HIV RT complexed with DNA template primer
- Superposition of nevirapine and TMC125
- TMC125 positioned in HIV-RT NNRTI-binding site
- Rilpivirine
- Molecular modeling of rilpivirine
- Protease inhibitors
- Protease inhibitors' mode of action
- Saquinavir
- Ritonavir
- Indinavir
- Nelfinavir
- Amprenavir
- Lopinavir
- Atazanavir
- Fosamprenavir
- Tipranavir
- Darunavir
- Hydroxyethylene bond
- HIV protease structure with PI in active site
- Fusion inhibitors
- Enfuvirtide
- Enfuvirtide structure
- Mechanism of action of enfuvirtide
- Co-receptor inhibitors
- Maraviroc
- Vicriviroc
- Mechanism of action of co-receptor antagonists
- AMD3100
- Indication for the clinical use of AMD3100
- The AMD3100 story
- Integrase inhibitors
- Raltegravir
- The two integrase catalytic reactions
- Elvitegravir
- Highly active antiretroviral therapy
- Drug combinations
- Evolution of fixed-dose combinations
- Drug evolution
- Acyclic nucleoside phosphonates
- (S)-HPMPA
- Prodrug of tenofovir
- Tenofovir disoproxil fumarate (TDF)
- Truvada
- Atripla
- Tenofovir DF and Emtricitabine-the top two drugs
- U.S. HIV market dynamics
- Tenofovir DF transformed HIV treatment
- HIV treatment in the developing world
- Number of patients treated, U.S.
- U.S. HIV patient share
- U.S. market share: HBV prescriptions
- GS 7340: dose response vs. Viread
- GS 7340: targeting lymphoid cells
- Future fixed-dose drug combination pill
- Forthcoming fixed-dose combinations
- Near term TDF single tablet regimens
- Chronic suppressive therapy limitations
- Prophylaxis
- Milestones in the development of tenofovir
- TDF in the prophylaxis of HIV infections
- Trials to test pre-exposure prophylaxis
- The CAPRISA 004 study
- Tenofovir gel reduced HIV acquisition
- Probability of HIV infection with tenofovir gel
- Chemoprophylaxis for HIV prevention (1)
- Chemoprophylaxis for HIV prevention (2)
- A showcase of compounds developed in IOCB
- Antonin Holy
- The 3 disciplines
Topics Covered
- Targets for anti-HIV therapy
- Reverse transcriptase
- Nucleoside reverse transcriptase inhibitors
- Nucleotide reverse transcriptase inhibitors
- Non-nucleoside reverse transcriptase inhibitors
- Protease inhibitors
- Fusion inhibitors
- Co-receptor inhibitors
- Integrase inhibitors
- Anti-HIV drug combinations
- Prophylaxis of HIV infections
Links
Series:
Categories:
Therapeutic Areas:
Talk Citation
De Clercq, E. (2011, August 30). Prospects of anti-HIV therapy and prophylaxis [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved December 1, 2024, from https://doi.org/10.69645/OVJT4624.Export Citation (RIS)
Publication History
Financial Disclosures
- Prof. Dr. Erik De Clercq has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.